

# Preliminary Results of a Phase I/Ib Study of Ibrutinib in Combination with TGR-1202 in Patients with Relapsed/Refractory CLL or MCL


Matthew S. Davids, MD, MMSc<sup>1</sup>, Haesook T. Kim, PhD<sup>1</sup>, Alyssa Nicotra<sup>1</sup>, Alexandra Savell<sup>1</sup>, Karen Francoeur, RN<sup>1</sup>, Jeffrey M. Hellman, PA-C<sup>1</sup>, Hari Miskin<sup>2</sup>, Peter Sportelli<sup>2</sup>, Thomas Rado, MD<sup>3</sup>, Asad Bashey, MD, PhD<sup>4</sup>, Laura Stampleman, MD<sup>5</sup>, Jens Rueter, MD<sup>6</sup>, Adam Boruchov, MD<sup>7</sup>, Jon E. Arnason, MD<sup>8</sup>, Caron A. Jacobson, MD<sup>1</sup>, David C. Fisher, MD<sup>1</sup>, and Jennifer R. Brown, MD, PhD<sup>1</sup>

<sup>1</sup>Dept. of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA, <sup>2</sup>TG Therapeutics, New York, USA, <sup>3</sup>Kadlec Clinic Hematology and Oncology, Kennewick, WA, USA, <sup>4</sup>Bone Marrow Transplantation Group of Georgia, Atlanta, USA, <sup>5</sup>Pacific Cancer Care, Salinas, CA, USA, <sup>6</sup>Eastern Maine Medical Center, Bangor, ME, USA, <sup>7</sup>St. Francis Medical Center, Hartford, CT, USA, and <sup>8</sup>Dept. of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, USA




## Background


### 1. Ibrutinib is highly active in R/R CLL and MCL




### 2. High risk subgroups have less durable response, resistance mutations have been observed



### 3. Hitting multiple BCR pathway targets may help overcome resistance



### 4. TGR-1202 is a potent and well-tolerated next-generation PI3K-delta inhibitor



## Aims/Methods

### Endpoints

**Primary**

- Maximum tolerated dose (MTD) of TGR-1202 when used in combination with ibrutinib in patients with relapsed or refractory CLL or MCL
- Safety and dose limiting toxicities (DLTs) of TGR-1202 in combination with ibrutinib in patients with relapsed or refractory CLL or MCL

**Secondary**

- Clinical response: ORR, CR, PR, PR-L, PFS, and remission duration
- Association of CLL prognostic factors (e.g. FISH, IGHV, etc.) with response

**Exploratory**

- Association of novel prognostic factors such as BH3 profiling and somatic mutations in *SF3B1*, *NOTCH1*, *MYD88* and *BCR/NFKB* with response

### Key Eligibility Criteria

**Inclusion**

- At least 1 prior standard therapy, an indication for therapy, and at least 1 measurable site of disease
- ANC  $\geq 0.5$  K/uL, platelets  $\geq 30$  K/uL (except pts w/  $>50\%$  CLL in marrow)
- Total bilirubin  $\leq 1.5$ X ULN, unless due to Gilbert's or hemolysis, then  $\leq 3.0$ X ULN, ALT/AST  $\leq 2.0$ X ULN or  $\leq 4$ X ULN if known liver involvement
- Creatinine  $\leq 2.5$  mg/dL OR calculated creatinine clearance  $\geq 50$  mL/min
- In Ph I portion, patients with prior BTK or PI3Ki therapy were eligible

**Exclusion**

- AutoSCT within 3 mo. or alloHCT within 12 mo. of study entry
- Post-allo patients must not have active GVHD and be off IS
- Active hepatitis, HIV infection, or central nervous system involvement
- Patients who require warfarin for anticoagulation

### Study Design


Dose Level	TGR-1202 Dose	Ibrutinib Dose CLL	Ibrutinib Dose MCL
1	400 mg	420 mg	560 mg
2	600 mg	420 mg	560 mg
3	800 mg	420 mg	560 mg

If > 2 DLTs in Cohort 1, 3- 6 pts will enroll in Cohort -1 as follows:

-1	200 mg	420 mg	560 mg
----	--------	--------	--------

If > 2 DLTs in Cohort -1, study will be terminated

- Parallel arms for CLL and MCL which escalated independently
- TGR-1202: oral, once daily in the morning
- Ibrutinib: oral, 420 mg daily in the evening for CLL, 560 mg daily for MCL
- Both agents continued until time of progression or unacceptable toxicity
- Standard toxicity assessments by CTCAE v4.03
- Response evaluations: after cycles 2, 5, 8, 12, and q6 mo. thereafter



### Statistical Design

- Phase I with a standard 3 + 3 design with up to 4 dose levels of TGR-1202
- 91% probability of dose escalation if the true rate of DLT is 10% and 17% probability of escalation if the true DLT rate is 50%
- Phase Ib expansion cohorts of 12 pts each in CLL and MCL
- Estimation of toxicity rates in 12 pt cohorts: 90%CI will be within +/- 25%
- Efficacy analyses: CLL: 2008 IW-CLL criteria, MCL: 2014 Lugano criteria

## Results

### Patient Characteristics (n=27)

- Histology: CLL n=17, MCL n=10
- Median age at enrollment: 66 years (range 48-83)
- Median # prior therapies:
  - CLL: 2 (range 1-6 with 2 prior ibrutinib, 2 prior PI3Ki)
  - MCL: 3 (range 2-5 with 2 prior ibrutinib)
- CLL prognostic markers
  - FISH: 9 pts with del(11q), 3 pts with del(17p), 1 pt without del(17p) but with *TP53* mut
  - IGHV: 7/16 (44%) unmutated, 2 pts with *NOTCH1* mut

### Safety Analysis (n=27)

- There were no DLTs, and the TGR-1202 recommended phase 2 dose (RP2D) for both CLL and MCL is 800 mg daily

CLL (n=17)	MCL (n=10)
<b>Hematologic toxicity :</b>	<b>Hematologic toxicity :</b>
• Neutropenia (35%, all Gr 3-4)	• Neutropenia (30%; 10% Gr 4)
• Thrombocytopenia (24%, all Gr 1)	• Thrombocytopenia (40%; 10% Gr 3)
• Anemia (35%, all Gr 1/2)	• Anemia (30%, 10% Gr 3)

All grade non-heme toxicities in $\geq 25\%$ of pts:	All grade non-heme toxicities in $\geq 25\%$ of pts:
• Diarrhea (41%, 35% Gr 1, 6% Gr 2)	• Diarrhea (60%, 50% Gr 1, 10% Gr 2)
• Nausea (35%, all Gr 1)	• Fatigue (50%, all Gr 1/2)
	• Nausea (30%, all Gr 1/2)
	• Transaminitis, dizziness, hypocalcemia (30% each, all Gr 1)

SAEs (in 1 patient each):	SAEs (none led to discontinuation):
• Amylase/Lipase elevation (Gr 3, required study drug discontinuation)	• Hypophosphatemia (n=2, both Gr 3)
• Atrial fibrillation (Gr 3)	• Amylase/Lipase elevation (n=1, Gr 3)
• CNS infection (Gr 3)	• Atrial fibrillation (n=1, Gr 3)
• Adrenal insufficiency (Gr 3)	• C. difficile infection (n=1, Gr 3)
	• Influenza A infection (n=1, Gr 4)

### Efficacy Analysis (n=21)

CLL (n=11)*				
Pt	TGR-1202 Dose	Best Response	FISH	IGHV status
01	400 mg	PR	13q + tri 12	Mut
02	400 mg	CR (BM MRD+)	14q32 + 13q	Unmut
03	400 mg	PR	13q	Mut
04#	600 mg	SD	17p + 11q + 13q	Mut
05	600 mg	PR	N/A	Mut
06#	600 mg	PR	14q32 + tri 12	Mut
07	800 mg	SD	13q	Mut
08	800 mg	PR	11q + 13q	Unmut
09	800 mg	PR	13q	Mut
10	800 mg	PR	13q	Mut
11	800 mg	PR	17p + 13q	Unmut

\*6 CLL patients included in the safety analysis have not yet reached their first response evaluation  
# Already on ibrutinib at time of study enrollment (4 months (Pt 04) and 3 weeks (Pt 06))

- ORR: 9/11 (82%)
- PR: 5/11 (45%)
- PR-L: 3/11 (27%)
- CR: 1/11 (9%) (confirmed with neg. BM)

MCL (n=10)			
Pt	TGR-1202 Dose	Best Response	Comment
01	400 mg	SD	45% SPD reduction
02	400 mg	PR	89% SPD reduction
03	400 mg	SD	Spleen 31 -> 23 cm WBC 342 -> 25
04	600 mg	PR	72% SPD reduction
05	600 mg	PR	74% SPD reduction
06	600 mg	PR	78% SPD reduction
07	800 mg	PD	Rapid PD in 1 <sup>st</sup> month
08	800 mg	PR	54% SPD reduction
09	800 mg	SD	13% SPD reduction
10	800 mg	PR	75% SPD reduction

- ORR: 6/10 (60%), all PRs
- Clinical benefit observed in 2 additional patients

## Conclusions

- We report to our knowledge the first clinical data on a PI3K plus BTK inhibitor doublet in B cell malignancies
- TGR-1202 + ibrutinib is well-tolerated in R/R CLL and MCL, with no DLTs observed in the phase I portion of this study
- The RP2D of TGR-1202 in combination with ibrutinib for both CLL and MCL was 800 mg daily
- The toxicities of TGR-1202 + ibrutinib are manageable and comparable to the additive toxicity profiles of the two agents given individually
- The preliminary efficacy results suggest a high response rate in both diseases, with a CLL patient achieving CR at 1 yr and several others approaching CR radiographically
- Accrual continues to this ongoing study

## Acknowledgements/Disclosures

-This investigator-sponsored trial (NCT02268851) is supported by TG Therapeutics (New York, USA) and a Leukemia & Lymphoma Society BCRP/TAP grant

- COI: Drs. Davids and Brown: SAB/consulting fees from Pharmacyclics, Inc. and Janssen, Dr. Davids: SAB for TG Therapeutics.

- Sportelli and Miskin: Employees of TG Therapeutics. All other authors have no relevant disclosures.

- Dr. Davids has an ASCO Career Development Award, and is a graduate of the ASH CRTI and ASCO/AACR Vail Workshop

- The authors thank the patients and their families for participating

Corresponding Author: [matthew\\_davids@dfci.harvard.edu](mailto:matthew_davids@dfci.harvard.edu)